Results 171 to 180 of about 18,928 (205)
Some of the next articles are maybe not open access.
On the Metabolism of Prasugrel
Revista Española de Cardiología (English Edition), 2011Hemos leido con interes el editorial de los Dres. Freedman e Iafrati recientemente publicado en REVISTA ESPANOLA DE CARDIOLOGIA. En dicho editorial, se menciona que el prasugrel es un inhibidor del receptor P2Y12 que no se metaboliza en el higado y no parece verse afectado por la variabilidad de la isoenzima P450.
Carlos Felipe, Barrera-Ramírez +2 more
openaire +2 more sources
2015
A comprehensive profile of prasugrel HCl is reported herein with 158 references. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for prasugrel HCl, its intermediates, and derivatives are fully discussed.
Mahmoud M H, Al Omari +4 more
openaire +2 more sources
A comprehensive profile of prasugrel HCl is reported herein with 158 references. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for prasugrel HCl, its intermediates, and derivatives are fully discussed.
Mahmoud M H, Al Omari +4 more
openaire +2 more sources
Journal of Cardiovascular Medicine, 2014
Clopidogrel is a prodrug that undergoes extensive enteric clearance and requires two-stage hepatic activation by cytochrome P450 (CYP) enzymes. This metabolic pathway is susceptible to genetic polymorphisms, resulting in a variable platelet inhibitory effect.
Nuccia, Morici +5 more
openaire +2 more sources
Clopidogrel is a prodrug that undergoes extensive enteric clearance and requires two-stage hepatic activation by cytochrome P450 (CYP) enzymes. This metabolic pathway is susceptible to genetic polymorphisms, resulting in a variable platelet inhibitory effect.
Nuccia, Morici +5 more
openaire +2 more sources